You have 9 free searches left this month | for more free features.

City

Hangzhou (1)

Jinan (1)

Qiqihar (1)

Shanghai (1)

Tianjin (1)

Zhengzhou (1)

Condition

Acute Myeloid Leukemia (1)

Classic Hodgkin Lymphoma (1)

Hematologic Malignancy (1)

Myelodysplastic Syndromes (1)

Solid Tumor (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Terminated (1)

Sign in for free

Phase

phase 1/phase 2 (2)

phase 1 (1)

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (3)

Collaborator

Institute of Hematology & Blood Diseases Hospital (1)

Intervention

imm01 (3)

azacitidine (1)

tislelizumab (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (3)

Study Type

Interventional (3)

imm01

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Hematologic Malignancy Trial in Tianjin (IMM01)

Terminated

Hematologic Malignancy

IMM01

Tianjin, Tianjin, China

Chinese Academy of Medical Sciences and Peking Union Medical Col

May 5, 2023

Solid Tumor, Classic Hodgkin Lymphoma Trial in China (IMM01, Tislelizumab)

Recruiting

Solid Tumor
Classic Hodgkin Lymphoma

IMM01
Tislelizumab

Hangzhou, China
+4 more

Apr 18, 2023

Acute Myeloid Leukemia, MDS Trial (IMM01, Azacitidine)

Not yet recruiting

Acute Myeloid Leukemia
Myelodysplastic Syndromes

IMM01
Azacitidine

(no location specified)

Nov 21, 2021